Aethlon Medical Initiates Dengue Fever Studies with Government of India Researchers.

SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) announced today that it has manufactured and shipped Hemopurifier[R] treatment cartridges for studies related to the treatment of Dengue Hemorrhagic Fever (DHF), an international health issue untreatable with antiviral drug and vaccine therapy. The Hemopurifier[R] studies are being performed by researchers at the National Institute of Virology (NIV), the Government of India's leading infectious disease research center and collaborating laboratory of the World Health Organization (WHO).

Initial testing of the Hemopurifier[R] will focus on in vitro studies that document the removal rate of Dengue virus and related toxins from blood. The global prevalence of dengue and virulent DHF has grown dramatically in recent decades. The disease is now endemic in more than 100 countries, and according to the World Health Organization, as many as 50 million cases of dengue infection occur each year. In vitro study data is expected to be available in 60 to 90 days.

About Aethlon Medical

Aethlon Medical has developed a first-in-class medical device to assist in the treatment of infectious disease. The device, known as the Hemopurifier[R], is positioned to be a broad-spectrum treatment for drug and vaccine resistant bioweapons, naturally evolving pandemic threats, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). On March 6, 2007, Aethlon submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) requesting permission to initiate human safety studies of the Aethlon Hemopurifier[R] as a treatment countermeasure against select category "A" bioterror threats. Additional studies to demonstrate utility of the Hemopurifier[R] as a countermeasure against bioterror threats are being conducted with researchers at The Centers for Disease Control and Prevention (CDC), The United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and The Southwest Foundation for Biomedical Research (SFBR). Category "A" bioterror threats are defined by the CDC as agents that pose a risk to national security; are easily disseminated or transmitted from person to person; result in high mortality rates; may cause public panic and social disruption, and require special action for public health preparedness. Global researcher, Frost & Sullivan, awarded the Hemopurifier[R] the 2006 Technology Innovation Award, and The AIDS Institute presented Aethlon with the 2007 Innovative HIV Life Sciences Leadership Award. The Company has also initiated research on a second generation Hemopurifier[R] that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.